https://european-biotechnology.net/wp-content/uploads/2025/11/AZ_Hypertension_1630732403_©Justlight-e1762842867116.jpg
560
955
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk 2025-11-11 06:36:43 2025-11-11 06:36:43 AZ’s baxdrostat mets endpoint in resistant hypertension
https://european-biotechnology.net/wp-content/uploads/2025/11/AdipocateAZ_1756950215_©gavi-e1762952818377.jpg
532
948
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk 2025-11-10 13:03:01 2025-11-10 13:03:01 AstraZeneca bolsters obesity portfolio with muscle‑preserving buy
https://european-biotechnology.net/wp-content/uploads/2025/11/mRNA_876396144_©AkuAku-e1762840618773.jpg
532
952
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk 2025-11-10 05:03:59 2025-11-10 05:03:59 Breakthrough study reveals stability key for mRNA
https://european-biotechnology.net/wp-content/uploads/2025/11/ObesityHeart_1486265640_©-Dzmitry-e1762845899404.jpg
533
948
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk 2025-11-09 17:17:32 2025-11-09 17:17:32 Semaglutide and tirzepatide significantly improve heart health
https://european-biotechnology.net/wp-content/uploads/2025/11/Novo-Trump_380460666_eC2ksQPRFWpkTgcwvE5bxK1xc4qVgn7B-e1762502390157.jpg
228
406
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk 2025-11-07 07:59:57 2025-11-07 07:59:57 Eli Lilly and Novo Nordisk slash obesity drug prices
https://european-biotechnology.net/wp-content/uploads/2025/11/Bildschirmfoto-2025-11-05-um-12.51.41-1030x468-1.png
468
1030
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk 2025-11-05 12:00:50 2025-11-05 12:00:50 QIAGEN acquires Parse Biosciences Inc for US$225m
https://european-biotechnology.net/wp-content/uploads/2025/11/bic_ingelheim-e1762275566553.webp
408
728
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk 2025-11-04 17:00:52 2025-11-04 17:00:52 Boehringer Ingelheim in US$570m deal with CDR-Life
https://european-biotechnology.net/wp-content/uploads/2025/11/AAVantgarde_552298461_-MikeCS-Images-1-1-e1762203895371.jpg
233
469
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk 2025-11-03 21:05:03 2025-11-03 21:05:03 AAVantgarde secures $141m Series B funding
https://european-biotechnology.net/wp-content/uploads/2025/10/NovoN_1068642359_O1jLzgF7qqt6oDRPEkTExQX6Lu9l4elr-e1761900762208.jpg
533
948
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk 2025-10-31 08:53:27 2025-10-31 16:32:03 Novo and Pfizer in Metsera takeover battle
https://european-biotechnology.net/wp-content/uploads/2025/10/NATO-BIOTECH-CONFERENCE-e1761733933149.jpeg
427
709
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk 2025-10-29 10:32:40 2025-10-29 10:32:40 NATO elevates biotech to defence priority
Scroll to top
Scroll to top
Scroll to top
